AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Personalis, Inc.
Video analysis: PSNL
All videosNo video analysis for this stock yet. Request one from our team.
News: PSNL
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Personalis, Inc. $PSNL Shares Bought by Bank of America Corp DE
Bank of America Corp DE lifted its position in shares of Personalis, Inc. (NASDAQ: PSNL) by 85.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 111,306 shares of the company's stock after buying an additional 51,273 shares during the period. Bank
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) has been assigned an average rating of "Hold" from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.
Personalis Reports Second Quarter Results and Recent Highlights
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments. Second Quarter and Recent Strategic and Operational Highlights Secured Medicare Coverage for IO Monitoring: Received Medicare coverage approval for NeXT Personal for immunotherapy monitoring for patients with late-stage solid tumors. Se.
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI
MONSEY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (Nasdaq: PSNL) (“Personalis”) to Tempus AI, Inc. (“Tempus”) for $16.25 per share.
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
